Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
Prostate Cancer
DRUG: Abarelix|DRUG: Goserelin plus Bicalutamide
Early castration rates, One week
Maintenance of medical castration, 48 weeks
Inclusion Criteria

* Males over 18 with documented advanced or metastatic prostate cancer

Outcome measures

* Comparative castration rates one week after starting therapy
* Degree of testosterone surge in the first month of treatment.
* Maintenance of medical castration during one year of therapy.
* Comparison of the treatments on QTc prolongation